News & Updates

Pemvidutide, an investigational, peptide-based GLP-1/glucagon dual receptor agonist, gains traction in the booming obesity drug market, delivering significant weight loss reductions in nondiabetic individuals with overweight or obesity in the phase II MOMENTUM trial.

Tofacitinib demonstrates safety and persistence in patients with psoriatic arthritis (PsA) who are mostly refractory to biologic and oral targeted synthetic disease-modifying antirheumatic drugs, results of a study have shown.

Patients with obesity-related heart failure with preserved ejection fraction (HFpEF) treated with semaglutide are more likely to show an improvement in NYHA functional class at 52 weeks than those who received placebo, according to a study.